J
Joshiawa Paulk
Researcher at Novartis
Publications - 27
Citations - 3886
Joshiawa Paulk is an academic researcher from Novartis. The author has contributed to research in topics: Protein degradation & Bromodomain. The author has an hindex of 16, co-authored 27 publications receiving 2738 citations. Previous affiliations of Joshiawa Paulk include Broad Institute & Harvard University.
Papers
More filters
Journal ArticleDOI
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter,Dennis L. Buckley,Joshiawa Paulk,Justin M. Roberts,Amanda Souza,Sirano Dhe-Paganon,James E. Bradner +6 more
TL;DR: In this paper, a chemical strategy that promotes ligand-dependent target protein degradation using as an example the transcriptional coactivator BRD4, a protein critical for cancer cell growth and survival, was devised.
Journal ArticleDOI
The dTAG system for immediate and target-specific protein degradation
Behnam Nabet,Justin M. Roberts,Dennis L. Buckley,Dennis L. Buckley,Joshiawa Paulk,Joshiawa Paulk,Shiva Dastjerdi,Annan Yang,Alan L. Leggett,Michael A. Erb,Matthew A. Lawlor,Amanda Souza,Amanda Souza,Thomas G. Scott,Sarah Vittori,Jennifer A. Perry,Jun Qi,Georg E. Winter,Georg E. Winter,Kwok-Kin Wong,Nathanael S. Gray,James E. Bradner,James E. Bradner +22 more
TL;DR: The dTAG system pairs potent heterobifunctional degraders and extensible tagging strategies to achieve immediate and reversible degradation of divergent proteins, facilitating biological investigation and drug target validation in cells and in mice.
Journal ArticleDOI
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
Gregory V. Kryukov,Gregory V. Kryukov,Frederick H. Wilson,Frederick H. Wilson,Jason R. Ruth,Jason R. Ruth,Joshiawa Paulk,Joshiawa Paulk,Aviad Tsherniak,Sara Marlow,Sara Marlow,Francisca Vazquez,Francisca Vazquez,Barbara A. Weir,Barbara A. Weir,Mark E. Fitzgerald,Minoru Tanaka,Minoru Tanaka,Craig M. Bielski,Craig M. Bielski,Justin M. Scott,Courtney Dennis,Glenn S. Cowley,Jesse S. Boehm,David E. Root,Todd R. Golub,Clary B. Clish,James E. Bradner,James E. Bradner,William C. Hahn,William C. Hahn,Levi A. Garraway,Levi A. Garraway +32 more
TL;DR: The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets and reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common “passenger” genomic alteration.
Journal ArticleDOI
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Georg E. Winter,Georg E. Winter,Andreas Mayer,Dennis L. Buckley,Michael A. Erb,Justine E. Roderick,Sarah Vittori,Jaime M. Reyes,Julia di Iulio,Amanda Souza,Christopher J. Ott,Justin M. Roberts,Rhamy Zeid,Thomas G. Scott,Joshiawa Paulk,Kate C. Lachance,Calla M. Olson,Shiva Dastjerdi,Sophie Bauer,Charles Y. Lin,Nathanael S. Gray,Michelle A. Kelliher,L. Stirling Churchman,James E. Bradner,James E. Bradner +24 more
TL;DR: These studies establish a mechanism-based rationale for the development of BET bromodomain degradation as cancer therapy and show that BET degradation prompts a collapse of global elongation that phenocopies CDK9 inhibition.
Journal ArticleDOI
A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader
Hai-Tsang Huang,Dennis Dobrovolsky,Joshiawa Paulk,Guang Yang,Ellen Weisberg,Zainab M. Doctor,Dennis L. Buckley,Cho Joong-Heui,Ko Eunhwa,Jaebong Jang,Kun Shi,Hwan Geun Choi,James D. Griffin,Ying Li,Steven P. Treon,Eric S. Fischer,James E. Bradner,Li Tan,Li Tan,Nathanael S. Gray +19 more
TL;DR: This study designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quantitative proteomics to discover 28 kinases, including BTK,PTK2, PTK2B, FLT3, AurKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable.